Navigation Links
NIH launches trial of investigational genital herpes vaccine
Date:11/8/2013

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.

Genital herpes is one of the most common sexually transmitted infections in the United States. Most genital herpes cases are caused by infection with herpes simplex virus type 2 (HSV-2); however, herpes simplex virus type 1 (HSV-1) can also cause genital herpes. An estimated 776,000 people in the United States are infected with HSV-2 or HSV-1 each year. There is no vaccine to prevent genital herpes.

"Although genital herpes is treatable, it is a lifelong infection that can exact a substantial psychological and physical toll on infected individuals and places them at higher risk of acquiring HIV," said NIAID Director Anthony S. Fauci, M.D. "Furthermore, mothers with active genital herpes infection at time of delivery can transmit the virus to their newborns, which can lead to severe illness and death."

"A protective vaccine would help to reduce significantly the spread of this all-too- common sexually transmitted infection," Fauci added.

Led by principal investigator Lesia K. Dropulic, M.D., of NIAID's Laboratory of Infectious Diseases, the trial will test an investigational HSV-2 vaccine candidate, called HSV529, for safety and the ability to generate an immune system response. The investigational vaccine manufactured by Sanofi Pasteur was developed by David Knipe, Ph.D., professor of microbiology and immunobiology at Harvard Medical School, Boston.

Preclinical testing of the candidate vaccine involved a 10-year collaborative effort between Dr. Knipe and Jeffrey Cohen, M.D., chief of NIAID's Laboratory of Infectious Diseases. The experimental product is a replication-defective vaccine, meaning that scientists have removed two key proteins from the vaccine virus so that it cannot multiply to cause genital herpes.

The clinical trial is expected to enroll 60 adults ages 18 to 40, who will be divided into three groups of 20 participants each. The first group will be of people who have been previously infected with HSV-2 and HSV-1 or solely with HSV-2; the second will have individuals who had been infected with HSV-1 only; and the third will consist of those who have not been infected with HSV-1 or HSV-2. The investigational vaccine is being tested among study participants who have previously been infected with HSV to determine if it may pose any safety issues.

Within each of the three groups, researchers will randomly assign participants to receive three doses (0.5 milliliters each) of the investigational HSV529 vaccine (15 participants) or a saline-based placebo vaccine (five participants). The three vaccinations will occur at study enrollment and again one month and six months later. Participant safety will be monitored throughout the course of the trial, and researchers will follow participants for six months after they have received their last dose of vaccine. Blood samples will be used to evaluate the candidate vaccine's ability to stimulate immune system responses to HSV-2, including production of virus-specific antibodies and T-cell responses. The study is expected to be completed by October 2016.

HSV-2 is generally transmitted through sexual contact and can spread even when the infected individual shows no symptoms. Although HSV-1 commonly infects the mouth and lips, it can also cause genital herpes. Once in the body, HSV migrates to nerve cells and remains there permanently, where it can reactivate to cause painful sores and blisters.


'/>"/>

Contact: Jennifer Routh
jennifer.routh@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. Mayo Clinic launches whole genome breast cancer study
3. Original research papers on acute cardiovascular care: ESC launches EHJ-ACVC
4. UCLA launches first face transplantation program in western US
5. Georgia Tech launches HomeLab to help companies evaluate home health technologies
6. US Drug Watchdog Launches Now Calls Transvaginal Mesh A Disaster For 100,000's of US Women Recipients And Offers The Names and Contacts Of The Best Women Attorneys
7. K9 CarFence™ Launches as Newest Innovation in Pet Transportation
8. Golden Gate Opportunity: Moravia Worldwide Launches Bay Area Operation
9. 'Music Makes It Better' Campaign Launches with Justin Bieber, Victoria Justice, and The Band Perry
10. Fieldtex Products Launches a New Wellness Rewards Service for Companies
11. Recruiting for Good Launches Pet Philanthropy Program to Collaboratively Fundraise for Kitt Crusaders an Animal Rescue Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2019)... ... August 17, 2019 , ... ... America’s Fastest-Growing Private Companies—the Inc. 5000 , For the 2nd Year In a ... Revenue Growth of 192% Percent , Inc. magazine today revealed that YellowTelescope LLC ...
(Date:8/16/2019)... ... August 16, 2019 , ... The clinical trial supply chain landscape is constantly ... , Join Just In Time Manufacturing Solutions Manager at Almac Clinical Services , ... 11am EDT (4pm BST/UK) on a journey through time as it relates to clinical ...
(Date:8/16/2019)... ... August 16, 2019 , ... ... market, has joined the esteemed Haute Beauty Network. , The Haute Beauty Network, ... to present Dr. Arnaoutakis as a hair restoration expert and our newest addition ...
(Date:8/15/2019)... ... 15, 2019 , ... With many students either starting college for the first time, and returning ... to the CDC , “there are about 20 million new cases of STDs each ... ages of 15 and 24. Young people are at greater risk of getting an STD.” ...
(Date:8/14/2019)... ... August 14, 2019 , ... Teguar Corporation has claimed the ... This list has long-been established as a mark of success for some of Americas ... Oracle. Teguar made the list in 2015, 2016 and 2017. This year, Teguar secured ...
Breaking Medicine News(10 mins):
(Date:8/21/2019)... ... August 21, 2019 , ... ... Healthcare’s Construction and Design Survey, has added Operational Readiness to its integrated ... overlay to clients’ capital projects, working with the clinical and operational leadership ...
(Date:8/21/2019)... ... August 21, 2019 , ... ... Module for its voice-activated notification and communication solution—with new features to help ... discharged patients. , Leveraging the innovative Amazon Alexa voice assistance technology, ...
(Date:8/19/2019)... ... August 19, 2019 , ... ... hosting their 2nd Annual National Sports Summit, August 25-26 at the Hyatt Place ... clinical leaders from all major professional sports programs to discuss progress made over ...
Breaking Medicine Technology: